Company profile
OCULAR THERAPEUTIX, INC
NASDAQ:OCULBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEXTENZA | approved | — | 104 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04945824 | — | terminated | 2021-06-01 | 2022-11-01 | Ocular Therapeutix, Inc. | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects |
| NCT04539548 | phase3 | completed | 2020-09-04 | 2023-12-21 | Ocular Therapeutix, Inc. | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract |
| NCT04050865 | phase3 | completed | 2019-08-05 | 2020-02-28 | Ocular Therapeutix, Inc. | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis |
| NCT05335122 | phase2 | completed | 2022-03-16 | 2024-01-24 | Ocular Therapeutix, Inc. | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) |
| NCT07235085 | phase3 | recruiting | 2025-11-17 | 2027-03-01 | Ocular Therapeutix, Inc. | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 208742 | 2018-11-30 | NDA | OCULAR THERAPEUTIX INC | |||||
Loading… | ||||||||